Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Hippocampus. 2018 Aug;28(8):586–601. doi: 10.1002/hipo.22962

Figure 4. Targeting dividing stem cells from P14–P21 leads to decreased DG neurogenesis, but does not deplete the stem cell pool in adulthood.

Figure 4

(A) Experimental timeline of P14–P21 VGCV treatment and TMX administration in GFAP-Tk/Nestin-CreERT2 mice. (B) Representative images of EYFP, DCX, NeuN, and GFAP staining in P14–P21 VGCV treated Tk− and Tk+ animals. (C) P14–P21 VGCV led to fewer EYFP+ cells in Tk+ versus Tk− males. (D) P14–P21 VGCV reduced the number of DCX+ immature and NeuN+DCX− mature neurons within the Nestin lineage of Tk+ compared to Tk− males. (E) P14–P21 VGCV led to fewer EYFP+ cells in Tk+ versus Tk− females. (F) P14–P21 VGCV reduced the number of DCX+ immature and NeuN+DCX− mature neurons within the Nestin lineage of Tk+ compared to Tk− females. (G) P14–P21 VGCV did not affect the number of RGLs, stellate astrocytes, or atypical astrocytes in the lineage of Tk+ males and (H) females compared to Tk− animals. (I) P14–P21 VGCV did not change the number of Nestin-S100β-, Nestin+S100β- or S100β+ RGLs in the Nestin lineage of Tk+ males and (J) females compared to Tk− animals. Scale bar represents 150 μM. GFAP inset is at 2× magnification. Data are expressed as mean ± SEM. *p≤0.05, **p<0.01, ***p<0.001